Tissue engineering has emerged as a new interdisciplinary field for the repair of various tissues, restoring their functions by using scaffolds, cells, and/or bioactive factors. A temporary scaffold acts as an extracellular matrix (ECM) analog to culture cells and guide the development of new tissue. In this chapter, we discuss the preparation of naturally derived scaffolds of polysaccharide origin, the osteogenic differentiation of mesenchymal stem cells cultured on biomimetic calcium phosphate coatings, and the delivery of biomolecules associated with ECM mineralization.
Tissue engineering has emerged as a new interdisciplinary field for the repair of various tissues, restoring their functions by using scaffolds, cells, and/or bioactive factors. A temporary scaffold acts as an extracellular matrix (ECM) analog to culture cells and guide the development of new tissue. In this chapter, we discuss the preparation of naturally derived scaffolds of polysaccharide origin, the osteogenic differentiation of mesenchymal stem cells cultured on biomimetic calcium phosphate coatings, and the delivery of biomolecules associated with ECM mineralization.
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bone morphogenetic protein BMP-2 bone morphogenetic protein-2 BMSC bone marrow stromal cell BMSSC bone marrow stromal stem cell CaP calcium phosphate ECM extracellular matrix FGF-1 fibroblast growth factor-1 FGF-2 fibroblast growth factor-2 IGF-2 insulin-like growth factor-2 the body through normal excretion processes [5, 6, 8, 9] . The scaffolds serve as temporary substrates for living cells as well as physical supports for tissue regeneration [10] . Adequate surface area and appropriate surface energy are also needed to permit cell adhesion, promote cell proliferation, and allow retention of differentiated cell functions [5] [6] [7] [8] 10] . In addition, sufficient mechanical stability of the scaffold material is necessary to maintain the desired shape and structure during cell culture in vitro and transplantation in vivo. Control of scaffold pore morphology is critical for controlling cell colonization rates and maintaining transport of oxygen, nutrients, and metabolic waste, as well as for supporting organization of the engineered tissue. Furthermore, angiogenesis, a requirement for the survival and success of vascularized tissues, can be affected by the porosity of the scaffold l. Pore morphology can also be expected to significantly affect scaffold degradation kinetics and the mechanical properties of the developing tissue [6, 11] . The scaffolds used for tissue-engineering purposes mimic the extracellular matrix (ECM) of the regenerating bone environment. Thus, in addition to serving as a mechanical support, a tissue-engineering scaffold may also be "informative" to the cells. An ideal three-dimensional (3D) construct for bone tissue engineering, above all other pertinent characteristics, should be simultaneously osteoinductive (capable of recruiting osteoprogenitor cells and stimulating their differentiation along the bone-forming cell lineage), osteoconductive (capable of supporting the formation of bone at the surface of the scaffold), and also resorbable and amenable to gradual replacement by newly formed bone [12] . In the medical field, consideration of biodegradation is a priority on the list of safety standards when choosing polymers as potential biomaterials for tissue-engineering applications. Naturally derived materials have recently gained interest, as they are structurally similar to the native ECM of many tissues; exhibit excellent biocompatibility; and induce minimal inflammatory response and tissue damage. Natural polymers may present a biologically active environment to the cells, since they usually contain domains that provide cues and can send important signals to guide cells at various stages of development [10] .
A method to potentially increase the biological activity of a bone tissue-engineering scaffold is to coat the surface of scaffolds with calcium phosphate (CaP). One of the main goals of using CaP coatings on bone tissue-engineering scaffolds is to promote osteoconduction by enhancing adhesion of osteogenic cells and ingrowth of bone into porous biomaterials [13] . New technologies have been developed to promote osteogenic activity of bone tissueengineering scaffolds. These approaches tend to integrate into the coatings osteoinductive or bioactive agents (e.g., enzymes and antibiotics), to immobilize constitutional elements of bone (e.g., growth factors, including bone morphogenetic proteins [BMPs] and other members of the transforming growth factor [TGF]-b superfamily), adhesion proteins (e.g., collagen, fibronectin, laminin, and vitronectin) and peptides (e.g., the arginine-glycine-aspartic acid [RGD] sequence) on the surface of biomaterials. Immobilization and/or delivery of bioactive molecules at specific sites have been exploited to enhance cell adhesion, differentiation, and other cell functions as well as to promote mineralization of the ECM of the tissueengineered bone constructs.
Scaffolds of Natural Origin -Polysaccharides
A large number of natural polymers, including polysaccharides, have been suggested as candidates for the production of scaffolds for bone tissue-engineering purposes. Polysaccharides are relatively complex carbohydrates. They are high molecular weight polymers having one or more monosaccharide repeating-units joined together by glycosidic biological activity of chitosan on bone regeneration has been confirmed in many studies [18, 45] . Chitosan can be easily fabricated into bulk porous scaffolds, films, microparticles, sponges, and beads. The feasibility of forming porous scaffolds permits wide application of this polymer in tissue engineering. This is mainly true for bone tissue-engineering applications because chitosan supports osteoblast proliferation and phenotypic expression [15] . Chitosan fiber meshes with appropriate mechanical properties, developed by Tuzlakoglu et al. [46] , exhibited bioactivity; this is a very important aspect for biomaterials used as bone tissueengineering scaffolds. Martins et al. [35] proposed the development of chitosan-based scaffolds with the capability of forming porous structures in situ following attack by specific enzymes (namely, a -amylase and lysozyme) present in the human body. In addition to the capability of forming pores in situ, other advantages these scaffolds have when compared with other conventional materials are their suitable mechanical properties and lack of toxicity. Coutinho et al. [47] studied the function of an osteoblastic-like cell line (SaOs-2) on chitosan blends with synthetic biodegradable polymers, and reported enhanced the osteoblastic activity. Costa-Pinto et al. [48] formulated scaffolds based on blends of chitosan and synthetic polyesters, and provided evidence that these scaffolds are cytocompatible. Furthermore, chitosan-based scaffolds promoted the attachment and proliferation of mouse mesenchymal stem cells (MSCs) [48] , which exhibited high levels of alkaline phosphatase activity and produced a mineralized ECM [48] .
Starch
Starch is one of the most abundant naturally occurring polymers with properties that make it attractive for several biomedical applications. Starch is found as insoluble granules of a -amylose (20-30%) and amylopectin (70-80%) [49] . Amylopectin polymers are highly branched structures containing (1→4)-a -D -glucose and (1→6)-a -D -glucose linkages, whereas amylose is much more linear with long stretches of (1→4)-a -D -glucose-linked monomer units. Starch is extremely difficult to process and is brittle when used without the addition of a plasticizer [49] . Over the years, several other materials have been blended with starch to improve its processability, including several synthetic [50] [51] [52] [53] [54] and natural polymers, such as polysaccharides [35, 55] and proteins [56] . Reis and coworkers [35, [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] have proposed use of starch-based scaffolds for biomedical applications. Starch exhibits low toxicity [35, 64] , biodegradability [35, [70] [71] [72] , and biocompatibility [73] [74] [75] , which are excellent characteristics for bone tissue-engineering applications. Compared with other biodegradable polymers available, starch is inexpensive, and above all, reusable. Specific enzymes present in the human body, namely a -amylase in the blood plasma, can easily degrade starch. The main enzymes involved in starch degradation are a -amylases, b -amylases, a -glucosidases, and other debranching enzymes.
An important consideration of biodegradable materials of natural origin being considered for use in the biomedical field is the host response to the degradation products. Starch degradation products are oligosaccharides that can be metabolized to produce energy. Due to their degradation by a -amylases, this constitutes another strategy to control and tailor the degradation of starch-based scaffolds. Martins et al. [35] developed a novel biodegradable matrix based on chitosan and starch, with the capability of forming a porous structure in situ following attack by specific enzymes (namely a -amylase and lysozyme) present in the human body. These researchers showed that pore size and distribution in the chitosan matrix is controlled by the location of the "sacrificial" phase (i.e., native starch) that is enzymatically degraded [35] . This same study reported an interesting approach for the control of matrix degradation in situ and consequent pore formation, which could result in scaffolds with mechanical properties appropriate for the initial stage of implantation [35] . Martins et al. [76] also studied the influence of a -amylase on the degradation of fiber-mesh scaffolds based on a blend of starch and poly( e -caprolactone) (SPCL) and demonstrated enhanced scaffold porosity and pore size and decreased average fiber diameter with time. Furthermore, culture of rat marrow stromal cells on SPCL fiber meshes (in medium supplemented with a -amylase) resulted in enhanced cell proliferation [76] .
Alginate
Alginate (alginic acid or algin) is a linear polyuronate containing D -mannuronic acid and L -guluronic acid that is abundant in the cell walls of brown algae. Due to the biocompatibility and gelation of alginate with certain divalent cations, it is widely used for cell immobilization and encapsulation. Alginate is soluble in aqueous solutions at room temperature and forms stable gels in the presence of calcium, barium, and strontium without chemical crosslinking agents [77] ; for this reason, the viability and biological activity of entrapped cells and biochemical agents are maintained in alginate gels. As a biomaterial, alginate has a number of advantages including biocompatibility and nonimmunogenicity, which are related to its hydrophilicity [78, 79] .
Several studies examined alginate sponges as scaffolds for tissue-engineering applications [78] and reported that their structural and morphological properties are appropriate for cell culture and proliferation as well as for neovascularization [78] . Other studies reported that alginate supports synthesis of pertinent ECM components by various cell types, and provides an amenable environment for cell encapsulation, drug delivery, and gene delivery [80] . Alginate also permits cotransplantation of multiple cell types and appropriate growth stimuli to promote, for example, the osteogenic phenotype [81] . Encapsulated bone marrow stromal cells (BMSCs) were studied for the purpose of healing bone defects in orthopedics [82] . Studies with gels containing MSCs and alginate beads loaded with vancomycin (a treatment for bone infections), reported that bone marrow-derived MSCs proliferated and expressed alkaline phosphatase, osteopontin, and collagen 1A1 genes [83] . Cai et al. [84] reported expression of bone-specific ECM markers when they examined the ectopic boneforming ability of BMSCs in combination with scaffolds made from alginate gel and implanted subcutaneously in nude mice for 8 weeks. Moreover, hydrogels such as alginate are effective substrates for both two-dimensional (2D) [85] and 3D [78, 85] cell cultures, indicating the suitability of alginate for tissue-engineering applications.
CaP Biomimetic Coatings
Ideally, tissue-engineering scaffolds should mimic, to the greatest degree possible, the properties of the native target tissue in an effort to promote, direct, and control regeneration of a specific, desired type of tissue. The term "biomimetics" is used to describe a branch of science that seeks to produce such "bioinspired" materials for a variety of applications.
Compared with other biomaterials, CaPs have a unique characteristic for bone mimicry and substitution. Their composition resembles that of bone mineral; most importantly, they can induce a biological response similar to that generated during bone remodeling, which involves resorption and formation of new bone tissue [86] . Osteoclasts are responsible for bone mineral degradation, resulting in bone resorption [86] . During bone resorption, the degradation products of CaP (calcium and phosphate ions) are naturally metabolized but do not cause abnormally increased calcium and phosphate levels in urine, serum, or organs [87] . It should be noted that osteoclasts degrade CaP in a similar fashion as they degrade natural bone [88] [89] [90] .
In 1972 Hench et al. [91] showed that "Bioglass" (that is, glass in the Na 2 O-CaO-SiO 2 -P 2 O 5 system), spontaneously bonded to living bone without formation of surrounding fibrous tissue. In the early 1990s, Kokubo and coworkers [92, 93] proposed that the essential requirement for a biomaterial to bond to living bone is the formation of bone-like apatite on the surface of the biomaterial when implanted in vivo. This in vivo apatite formation can be reproduced in vitro using simulated body fluid, which is a solution containing inorganic ion concentrations similar to those of human extracellular fluids but without any cells or proteins [94] . Under such in vitro conditions, the formed layer consists of carbonate apatite with small crystallites and low crystallinity [94] . This apatite is referred to as "bone-like apatite" due to its similarity to apatite present in natural bone.
Biomimetic methodology for coating biomaterials with a bone-like apatite layer has been described in several publications [92, [95] [96] [97] [98] . This technique mimics the natural biomineralization processes, which involve controlled crystal phase nucleation and growth. The main advantage of the biomimetic methodology is the use of physiological conditions (pH 7.4 at 37°C) simulating the conditions under which apatite is formed in bone. Moreover, this technique allows incorporation of proteins and bioactive agents into CaP coatings without compromising bioactivity of the organic compounds [96, [98] [99] [100] [101] . In 1997, Reis et al. [95] adapted the methodology developed by Kokubo and used bioactive glass as a precursor to nucleation and growth of CaP films on starch-based polymers. Briefly, for the preparation of biomimetic CaP coatings based on the methodology previously developed by Abe et al. [92] and Kokubo [93] and adapted by Reis et al. [95] , the materials under consideration were first impregnated with bioactive glass, and were then immersed in simulated body fluid (1.0 SBF) solution for several days at 37°C; this phase is known as the "nucleation stage" and allows formation of CaP nuclei. In order to accelerate apatite formation, the biomaterials were subsequently immersed at 37°C in simulated body fluid solution (1.5 SBF) with an ionic concentration 1.5-fold greater than physiological levels; this condition enhances CaP nuclei growth. The CaP biomimetic coatings, which are thus formed, exhibit osteoconductive properties that will be discussed later on in this chapter.
Osteoconductivity
Scaffolds for bone tissue engineering should be osteoconductive; that is, able to support formation of bone within and/or upon the scaffold. Osteoconductivity has been observed when porous structures were implanted into or adjacent to bone. In such cases, osteoprogenitor cells migrated into pores and filled the porous structure with newly formed bone. This process is characterized by an initial ingrowth of fibrovascular tissue that invades the porous structure followed by later development of new bone directly within it [102] . Hydroxyapatitebased materials are osteoconductive, provided that fully differentiated osteogenic cells are available at the site of implantation [12] . Adsorption of growth factors from the local milieu and from the blood circulation contributes to the osteoconductivity of hydroxyapatite by creating suitable conditions for bone formation when implanted in an osseous environment in vivo. Many relatively insoluble CaP materials are osteoconductive, and, in some cases, may induce extraskeletal new bone formation (i.e., they are osteoinductive). 
Osteoinductivity
Osteoinduction is the process by which stem and osteoprogenitor cells are recruited to the bone-healing site and stimulated to undergo osteogenic differentiation [103] . Osteoinductivity implies the ability of chemical compounds to induce osteogenic differentiation of uncommitted progenitor cells [12] . It has been proposed that biomaterials do not have an osteoinductive character in the absence of appropriate osteoinductive agents, such as certain BMPs and other bioactive molecules [104] . However, several studies have reported that some CaP biomaterials [105] [106] [107] , namely CaP coatings [107, 108] , may be osteoinductive. These CaP biomaterials may induce bone formation at extraskeletal sites without addition of osteogenic cells or bioactive agents. Hydroxyapatite is not osteoinductive because it cannot induce osteogenic differentiation of progenitor cells when implanted in a nonosseous environment, such as skin and muscle [12] .
Incorporation of Biomolecules into CaP Biomimetic Coatings
Numerous attempts have been made to improve the osteoconductivity of biomaterials. Coatings of CaP expedite osteoconduction and bone ingrowth at the surface of bone substitutes and, therefore, are useful strategies in tissue-engineering endeavors for the regeneration of bone tissue. However, a methodology that enables regeneration of bone tissue should not only expedite osteoconduction, but also osteoinduction through biochemical pathways [109] [110] [111] [112] . It is known that BMPs can be incorporated into CaP implants (with adequate 3D geometry) to promote osteogenesis [112, 113] ; the surface of such implants, however, will be rapidly conditioned by several highly concentrated molecules [114] . For this reason, other types of delivery-specific approaches have been investigated as alternatives that further functionalize and enhance the potential of CaP coatings. Specifically, the CaP biomimetic coatings have been used as a carrier of various molecules, including osteoinductive agents such as BMPs [115] [116] [117] , other proteins [101, [118] [119] [120] , enzymes [96, 98, 101] , and antibiotics [13, 121] .
Biomimetic CaP coatings, produced as described in earlier parts of this chapter, are deposited onto surfaces under physiological temperature and pH [110] , enabling coprecipitation and consequent incorporation of biologically active molecules [99] . This approach circumvents difficulties common to plasma spraying techniques. By using low temperatures, biomimetic processes can be applied not only to highly resistant materials (e.g., metallic alloys) but also to polymeric and naturally derived materials (e.g., chitosan, starch, and collagen) for implantation [122] .
The major objective of CaP coatings is to provide appropriate biological composition and to improve the quality of the surfaces of various materials used for orthopedic applications. The conditions under which such a coating is prepared affect conformational stability of incorporated biomolecules, and thus the bioactivity and shelf-life of the final product. Such coatings, which are structurally and chemically comparable to the mineral component of bone, can possesses favorable bioactive properties that may facilitate outcomes in cases of critical clinical need [13, 123] .
This alternative coating technique may be used to produce systems with several advantages, such as reduction of burst release of incorporated molecules into the biological milieu. In this case, biomolecules incorporated in the inorganic phase are gradually released as the latticework undergoes degradation. The advent of the slow degradation of the coating modulates delivery of bioactive agents. Slow release of these chemical compounds may improve the osteoinductive capacity of the implant material [100, 124] . One of the potential applications of CaP coatings pertains to the incorporation of bioactive agents and proteins. Azevedo et al. [101] used a biomimetic technique and successfully incorporated bovine serum albumin and a -amylase into a CaP coating on the surface of a starch-based polymer. In that study, the properties of the resultant biomaterial were tailored by judicious choice of specific enzymes and their incorporation at different compositions and combinations into CaP coatings that retained their bioactivity [101] . Efficient incorporation of active a -amylase into biomimetic coatings controlled the degradation rate of starch-based biomaterials. Similar results and applications were achieved with chitosan scaffolds after incorporation of lysozyme [96, 98] . Martins et al. [96, 98] incorporated lysozyme into CaP coatings on the surface of chitosan scaffolds in order to control the degradation rate of chitosan and subsequent formation of pores. Furthermore, since lysozyme has antibacterial properties, these coatings may be used as a carrier for its sustained release, potentially mitigating infection at the implantation site. Several studies reported in the literature addressed incorporation of BMPs into biomimetic CaP layers [110, 116, 123, 125] . These studies indicated that CaP coatings have the potential for sustained delivery of many other bioactive agents. Liu and coworkers [99] demonstrated that BMP-2 retained its osteoinductivity when delivered from biomimetic systems and that the osteoconductivity of implant material surfaces was affected by BMP-2 and its delivery mode [123] .
In summary, the results discussed in this section support the strategy of adding osteoinductive signaling molecules into CaP biomimetic coatings for the purpose of inducing bone growth.
Osteogenic Differentiation of Marrow Stromal Cells and Mineralized ECM Production In Vitro
Biomaterials and scaffolds considered for bone tissue engineering are often evaluated in vitro for their ability to support adhesion, proliferation, and differentiation of progenitor cells along the osteogenic pathway prior to being evaluated in vivo. In vitro cell-scaffold interactions are determined using osteoblasts, osteosarcoma cell lines, and osteoprogenitor cells. The scaffolds used for this purpose mimic the ECM of bone and play a crucial role in supporting cell functions and differentiation, but may also be used to deliver biomolecules.
Osteoblastic differentiation of MSCs comprises cell proliferation, cell maturation, and matrix mineralization. During these phases, cells synthesize and secrete alkaline phosphatase, type I collagen, and other noncollagenous ECM proteins, such as osteocalcin, osteopontin, osteonectin, and bone sialoprotein. Mineralization occurs through accumulation of calcium and phosphorous in the ECM.
BMSCs Versus MSCs
The osteoprogenitor cells used for bone tissue-engineering purposes are derived from various tissue sources. Bone marrow stroma consists of a heterogeneous cell population that provides structural and physiological support for hematopoietic cells [126] . Bone marrow contains three main cell types: endothelial cells, hematopoietic cells, and stromal cells. Friedenstein [127, 128] were the first to identify in bone marrow cell populations with strong osteogenic potential. When marrow cells are plated at low cell densities, BMSCs form colonies known as "colony-forming unit-fibroblasts"; this term indicates that each colony derives from BookID 158674_ChapID 13_Proof# 1 -8/4/2009 a single proliferating progenitor [129] . The term "BMSCs" is applied to isolated bone marrow cells with potential to form connective tissues [129] .
Due to their high proliferation potential, BMSCs can be expanded in culture to obtain large numbers of cells starting from a small sample of bone marrow aspirate. The BMSC population contains precursor cells capable of extensive proliferation and differentiation into several phenotypes. Furthermore, BMSCs maintain their multipotential capacity during prolonged culture and multiple passages in vitro. Among these BMSCs there is a subpopulation of undifferentiated multipotent cells able to generate "mesenchyme," the mass of tissue that develops from the mesoderm of an embryo. This cell population is present in all postnatal tissues and is referred to as "MSCs" [130, 131] . In the past, researchers working with cells from the bone marrow used different names to refer to the same cells. This practice lead to nomenclature confusion; for example, BMSCs have been referred to as multipotent adult progenitor cells, MSCs, bone marrow stromal stem cells (BMSSCs), and mesodermal progenitor cells [132] . What is presently known is that, if appropriately induced, these cells can also differentiate along pathways different from those associated with the cells' tissues of origin [133] .
Stem cells are able to provide replacements for various differentiated cell types. The use of MSCs has several advantages, as they have unique biological properties, are capable of extensive replication in culture in an undifferentiated state, and can differentiate along multiple pathways to form various cells from a number of tissues, including bone, cartilage, and fat [4] . Identification of stem cells using surface markers has not been definitive either, because similar markers are also present on nonstem cells, or because a particular marker may only be temporarily expressed on a stem cell at a certain stage or under specific conditions.
Osteogenic Differentiation
In addition to being osteoconductive and osteoinductive, an ideal scaffold should also be osteogenic (that is, containing living cells capable of differentiation into osteoblasts). Differentiation of MSCs along the osteoblastic lineage in vitro starts with a period of cell proliferation followed by synthesis and deposition of ECM components by the cells; accumulation of calcium finally leads to mineralization of the ECM. To induce osteogenic differentiation in MSCs, the culture medium is usually supplemented with osteogenic agents such as dexamethasone, b -glycerophosphate, and ascorbic acid.
Dexamethasone, a synthetic glucocorticoid, stimulates MSC proliferation and supports osteogenic lineage differentiation [134] [135] [136] . Organic phosphates, such as b -glycerophosphate, also support osteogenesis by contributing to mineralization of the ECM and modulating osteoblast function [136] [137] [138] . Free phosphates can also induce expression of osteogenic protein markers, such as osteopontin [136, 139] . Other supplements, such as ascorbic acid, enhance collagen synthesis and upregulate alkaline phosphatase expression in bone cells. Ascorbic acid stimulates marrow stromal cells to differentiate along the osteoblast lineage [139] [140] [141] . Furthermore, ascorbic acid promotes osteogenic induction evidenced by increased alkaline phosphatase activity and production of osteocalcin in osteogenic cultures [142] .
Martins et al. [76] used marrow stromal cells cultured on starch-poly( e -caprolactone) blend scaffolds in static cultures and reported that the enzyme lipase enhanced osteogenic differentiation and promoted deposition of a mineralized ECM. The BMP family of growth factors is frequently used for osteoinduction. BMP-2 increases calcium-containing nodule formation and the calcium content of osteogenic cultures in vitro [136] . The TGF-b superfamily contains a large number of growth factors with different functions, many of which regulate cell proliferation and ECM production. Fibroblast growth factors (FGFs), namely
FGF-1 and FGF-2, are produced by oseoblasts and are constituents of the bone matrix s . Insulin-like growth factors (IGF) stimulate osteogenesis; IGF-2 is the most abundant growth factor found in bone matrix. Gomes et al. [143] demonstrated that an in vitro generated bonelike ECM produced by marrow stromal cells contains bioactive growth factors including TGF-b 1, FGF-2, vascular endothelial growth factor, and BMP-2. Pham et al. [144] reported that the gene expression profiles of various bone-related growth factors and ECM proteins in MSCs cultured in osteogenic media were upregulated; these chemical compounds are present in native bone tissue. Costa-Pinto et al. [48] studied the osteogenic differentiation of a mouse MSC line (BMC9) cultured on novel melt-based chitosan/polyester scaffolds and reported high levels of alkaline phosphatase activity and formation of a calcified ECM; these results are evidence of differentiation of the cells along the osteogenic pathway.
Expression of osteoblast phenotype markers in culture defines three different phases of bone-related activities: cell proliferation, ECM maturation, and ECM mineralization. During active cell proliferation, growth-related genes are expressed, and minimal levels of type I collagen are observed [145] . Following this phase, a period of matrix maturation occurs when alkaline phosphatase is maximally expressed. Finally, the ECM becomes mineralized, the third period of the bone developmental sequence [145] . There are two transition periods between the aforementioned developmental periods: the first occurs at the end of proliferative period and the second when expression of osteoblastic phenotype markers (such as osteocalcin and osteopontin), become significantly elevated with the onset of mineralization [145] .
Alkaline phosphatase activity, an early marker of the osteoblastic phenotype, is upregulated at the onset of cell differentiation but subsequently decreases as cell differentiation progresses. Another marker of bone formation is calcium-containing mineral deposits in the ECM. To detect mineral deposition, tetracycline-HCl, a fluorochrome-labeling agent for bone tissues [146] , is added to the osteogenic culture media [147] . Tetracycline accumulates at sites of bone formation and fluoresces brightly when activated with appropriate fluorescent light. Qualitative (or semiquantitative) analysis of calcium-containing mineral deposits in bone cell cultures uses the von Kossa, alizarin red, and methylene blue/basic fuchsin staining methods [147, 148] . An important artifact, which should be kept in mind when using these analyses, is that the ECM uptakes calcium independently from cell-mediated mineral deposition. For this reason, confirmation of the results obtained using the aforementioned staining methods should be complemented with data from either diffraction or spectroscopy methods such as thin-film X-ray diffraction and Fourier-transformed infrared spectroscopy [76, 148, 149] .
Expression of osteopontin occurs during the mid-to late-stages of osteogenic differentiation of MSCs [150] . Osteopontin is an extracellular protein secreted by differentiating osteoblasts that is upregulated both during cell proliferation and at the onset of ECM mineralization. Osteocalcin, another late-stage marker of osteoblastic differentiation, can be assessed using commercially available immunoassays. Immunohistochemistry using specific antibodies to detect the presence of growth factors, bone-and ECM-related proteins, and enzymes is well established and widely used. Real-time reverse transcriptase polymerase chain reaction is used to determine expression of bone-related genes, such as osteoblast marker genes, growth factors, and ECM biomolecules, in MSCs [144] .
Bone-Specific Matrix Proteins
The bone matrix is not only composed of a mineralized phase, but also of an organic phase containing collagenous and noncollagenous proteins, matrix metalloproteinases, proteoglycans, and glycoproteins. Bone formation involves regulated secretion, deposition, and BookID 158674_ChapID 13_Proof# 1 -8/4/2009 removal of a complex array of these matrix proteins, which appear in a defined temporal and spatial sequence [12] . Mineralization also dictates the spatial orientation of matrix deposition [12] . Most proteins originally thought to be unique to the bone ECM were subsequently proven to be expressed in many other tissues of the body. Osteocalcin is the only protein still considered to be bone specific in bone mineralization [12] .
As discussed previously, alkaline phosphatase is considered an early-stage marker of osteoblastic differentiation [145] and is expressed during the postcell proliferative period of ECM deposition. Type I collagen, the major ECM protein of bone, provides a template for subsequent mineralization [151] . Alkaline phosphatase, collagen, and osteonectin are expressed at high levels near the end of cell proliferation and during the period of ECM deposition and maturation [139] .
Osteopontin and bone sialoprotein, N -linked glycoproteins containing integrin-binding RGD motifs, are involved in cell-matrix interactions. Osteopontin is widely distributed in different tissues, whereas bone sialoprotein is highly enriched in bone and skeletal cartilage [152] . Osteopontin, a phosphorylated glycoprotein associated with the early stages of osteogenesis that precede mineralization, is secreted by osteoblasts into the mineralizing ECM during bone development [139, 153] . In bone, bone sialoprotein is expressed by fully mature osteogenic cells capable of depositing mineralized matrix [152] . Extracellular bone sialoprotein localizes to newly formed, mineralized bone matrix; its distribution coincides with that of mineral deposits [154] . Bone sialoprotein, a protein expressed during the early phases of bone deposition, controls both mineral formation and cell-matrix interactions [155] . This protein is used as a marker of initial bone formation [155] . The function of bone sialoprotein in bone, which has not been completely elucidated yet, may be related to the regulation of physiological mineralization of skeletal ECMs [154, 156] . Osteocalcin is another marker of late-term osteogenic differentiation associated with osteoblast-mediated matrix deposition and mineralization [157, 158] . Expression of osteopontin, osteocalcin, and bone sialoprotein occurs later during the third period of ECM mineralization.
Summary
Surface modification of biomaterials uses methods that mimic biomineralization and enable incorporation of bioactive molecules and agents; such treatments can improve both in vitro and in vivo osteogenic differentiation. The main objective of CaP coatings is osteoconduction and enhanced adhesion of osteogenic cells onto biomaterial surfaces. Because CaP coatings have structures and chemical properties similar to those of native bone, they have great potential and promise to increase bone ingrowth in areas of clinical need.
Because they lack essential properties, such as bioactivity and osteoinductivity, most currently available polymers present limitations for bone-related biomedical applications. In this respect then, the biomimetic coating technique discussed in the present chapter has the potential to impart these essential properties to biomaterials. Since CaP layers can be applied on 3D scaffolds, the biomimetic-coating approach has been receiving increased attention in the bone tissue-engineering field.
Moreover, CaP coatings have been considered as a potential carrier for the delivery of various biomolecules, chosen for their physicochemical and biological properties as well as for their osteoconductivity. Complementing the CaP biomimetic coating approach, incorporation of biomolecules provides osteoinductive properties to biomaterials. Since this method is carried out under physiological conditions, proteins, enzymes, and other bioactive agents can be incorporated into CaP layers without loss of their bioactivity. A major advantage is the fact that the biomaterial-CaP coating-biomolecule can simultaneously exhibit osteoinductive and osteoconductive properties, because it can act as a carrier system for the controlled release of multiple biologically active proteins. Incorporation of enzymes into CaP layers coated on the surface of scaffolds (using the biomimetic-coating technique) can be also used to control the degradation rate of the material substrate in vivo. An integrated approach combining a material scaffold, CaP coatings, bioactive molecules and/or enzymes, and in vitro cell cultures may provide an optimal environment for cell adhesion and osteogenic differentiation as well as generate a mineralized ECM containing select bioactive molecules.
Incorporation of bioactive molecules into CaP coatings on scaffolds for tissue-engineering applications has the potential to provide advanced, tissue-specific constructs to promote improved alternative treatment of bone pathologies and trauma. The present chapter summarized the results of studies that used biomolecules important to bone tissue engineering. Further research is needed to elucidate important aspects such as details of the release profiles of entrapped bioactive molecules, retention of their bioactivity, etc. Establishment and further development of nature-inspired techniques to design and formulate novel biomaterials could provide the next generation of effective scaffolds for bone tissue engineering.
